Alexion shoots down 'proactive' sale demand from activist investor

Alexion
Alexion touted its M&A expertise in its rebuttal to the sale request. (Alexion)

Alexion has withstood its fair share of gales in recent years after a wholesale shakeup at the top and a shift toward an M&A-focused strategy underway. Now, despite one activist investor's call for a "proactive" sale, Alexion's board has decided to stay the course.

Alexion's directors opted not to pursue a sale after a "good faith" conversation with Elliott Advisors—an affiliate of infamous proxy brawler Elliott Management, which requested the sale, the company said. 

"It is highly unusual, if not unprecedented, for a biopharmaceutical company of our size and maturity to proactively launch a sale process," Alexion said in a release. "We do not believe this approach is the best path for driving shareholder value."

A spokesperson for Elliott Management could not be reached by press time. 

As part of its rebuttal to Elliott's request, the board touted its corporate strategy, including its "M&A leadership, including evaluating, negotiating and executing on numerous mergers, acquisitions and sales of major companies throughout their careers." 

RELATED: Alexion replaces CFO Clancy and his 'legendary caution.' Could an M&A spree follow?

Suggested Articles

The FDA has found a handful of issues with Biocon’s small molecule API facility in Bengaluru, India.

Pfizer plans to sell two assets to its Mylan-Upjohn spinoff, adding $598 million in revenues—but that won't do much for its profits, analysts warned.

AstraZeneca has made a hefty investment in Brilinta with billions in R&D costs. But will that sunk cost ever turn a profit for the British drugmaker?